10 withdrawn, 4 completed, 4 terminated, 1 unknown. 19 Phase 1, 15 Phase 2.
By phase and status
Follow Omacor: new trials by email Literature Review of Omacor trials Research Report on Omacor
Trials (filtered) newest first · largest first
All 19 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | | 2018-08-01 | 2025-02-21 |
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
Omacor, Pritor, Omacor + Pritor - Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Unknown | 48 | 2018-02-01 | 2018-02-22 |
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | | 2018-02-01 | 2025-02-21 |
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | 4 | 2017-12-28 | 2024-05-22 |
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-21 |
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-21 |
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-24 |
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-24 |
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Avelumab, Bevacizumab, Capecitabine - Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-21 |
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-21 |
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | | 2017-12-01 | 2025-02-21 |
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ALT-803, ETBX-011, GI-4000 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | 6 | 2017-11-06 | 2024-12-12 |
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Epanova, Lovaza - Severe Hypertriglyceridemia | Phase 1 | Completed | 30 | 2014-10-01 | 2016-06-20 |
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
warfarin, omefas, omega-3-acid ethyl esters - Hypertriglyceridemia | Phase 1 | Completed | 52 | 2011-08-01 | 2015-04-24 |
Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease
Lovaza (omega-3-acid ethyl ester), Corn oil - Liver Disease, Short Bowel Syndrome | Phase 1 / Phase 2 | Withdrawn | | 2011-01-01 | 2017-06-22 |
The Effects of Lovaza® in Acute Myocardial Infarction
Lovaza®, The placebo contained 1 gram of corn oil in each capsule. - Myocardial Infarction | Phase 1 / Phase 2 | Terminated | 4 | 2010-06-01 | 2017-11-06 |
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
Lovaza - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | 15 | 2009-09-01 | 2021-10-20 |
The Effects of Omega-3 Fatty Acids on Aspirin Resistance
Aspirin, Lovaza, Both Aspirin and Lovaza - Increased Drug Resistance | Phase 1 / Phase 2 | Completed | 27 | 2008-11-01 | 2012-11-06 |
Study of Fish Oil to Reduce ALT Levels in Adolescents
Omega-3-acid ethyl esters, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver | Phase 1 | Terminated | 3 | 2008-06-01 | 2016-01-29 |
Conditions studied
Hypertriglyceridemia (4) · Myocardial Infarction (2) · Pancreatic Neoplasms (2) · Acute Coronary Syndrome (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cardiovascular Diseases (1) · Colorectal Neoplasms (1) · Fatty Liver (1) · Hyperlipidemias (1) · Liver Diseases (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Non-alcoholic Fatty Liver Disease (1)
Sponsors
ImmunityBio, Inc. (11) · AstraZeneca (2) · University of Rochester (2) · Boston Children's Hospital (1) · Boston University (1) · DongKoo Bio & Pharma (1) · Sanford Research (1)
Countries
United States (9) · Canada (1) · South Korea (1)
Top investigators
Andrea L Lawless, MD (1) · Carine M Lenders, MD, MS, ScD (1) · Gregory C Shearer, PhD (1) · Michael H Davidson, MD, FACC (1) · Min Kyu Park, MD (1) · Robert Block, MD, MPH (1) · Robert C Block, MD, MPH (1) · Tom Jaksic, MD, PhD (1)
Results publications
PMID 25393536, PMID 32473640